CORONA Remedies Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
CORONA Remedies, a Gujarat-based pharmaceutical company that recently listed on NSE and BSE on December 15, 2025, reported its first set of quarterly results post-IPO. Consolidated revenue from operations grew 15.1% YoY to ₹361.13 Cr in Q2 FY26 and 17.0% YoY to ₹707.67 Cr in H1 FY26. Profit after tax rose 21.8% YoY to ₹52.32 Cr in Q2 and 35.1% YoY to ₹98.52 Cr in H1 FY26. EBITDA for Q2 stood at ₹78.47 Cr (margin 21.7%) and H1 at ₹148.25 Cr (margin 20.9%). Return metrics were strong with annualised RoE of 31.1% and RoCE of 49.7%. Operating cash flow for H1 was healthy at ₹113.44 Cr (76.5% of EBITDA). The statutory auditor Deloitte Haskins & Sells LLP issued an unqualified limited review report on both standalone and consolidated results.
Strong debut quarter with double-digit revenue growth, expanding PAT growth, and high return ratios. The clean auditor review and first post-IPO disclosure are positive for investor confidence, though the stock may already reflect much of this given the recent listing.